The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Canada's health regulator has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, to reduce the risk of non-fatal myocardial ...

Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company that specializes in the discovery, development, ...

Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, marking it as the first treatment in the country authorised to assist in chronic weight management and to reduce the risk ...

Novo Nordisk is a global leader in healthcare, renowned for its groundbreaking innovations in diabetes and obesity treatment, notably through products like Ozempic and Wegovy. Under the leadership ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.